Amicus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Amicus Therapeutics

08/08/2023 13:00

* Amicus Therapeutics Inc  FOLD.OQ  reported a quarterly
adjusted
loss of 15 cents​​ per share for the quarter ended in June. The
mean expectation of twelve analysts for the quarter was for a
loss of 12 cents per share.
    * Revenue rose 17.1% to $94.50 million from a year ago;
analysts
expected $89.87 million. 
    * Amicus Therapeutics Inc's reported EPS for the quarter was
a
loss of 15 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * Amicus Therapeutics Inc shares had fallen by 0.2% this
quarter and gained 2.7% so far this year.
    * The company reported a quarterly loss of $43.23 million.
    * Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 12:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.12          -0.15          Missed
 Mar. 31 2023      -0.15          -0.18          Missed
 Dec. 31 2022      -0.13          -0.19          Missed
 Sep. 30 2022      -0.19          -0.12          Beat